期刊
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY
卷 50, 期 2, 页码 252-272出版社
HUMANA PRESS INC
DOI: 10.1007/s12016-014-8444-9
关键词
Eosinophils; Eosinophilic diseases; Biologics; Monoclonal antibodies; Asthma; Hypereosinophilic syndrome; Eosinophilic granulomatosis with polyangiitis; Churg-Strauss syndrome; Nasal polyposis; Eosinophilic esophagitis
Eosinophils can regulate local and systemic inflammation, and their presence in higher numbers appears to play an important role in the pathology of various atopic and inflammatory diseases. Eosinophil maturation, recruitment, and survival depend on several cytokine regulators, including interleukin (IL)-5, IL-4, and IL-13 as well as growth factors such as GM-CSF. Over the last decade, the approach to treating eosinophilic diseases has changed greatly. A number of biologic modulators have been developed to target eosinophilic inflammatory pathways, and their usage has resulted in variable clinical improvement in the treatment of eosinophilic-associated conditions. Novel targeted therapies that are safe and effective for treating these disorders are being investigated. This review summarizes the clinical use of biologic agents that have been studied in clinical trials or approved for treating eosinophilic diseases.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据